89 related articles for article (PubMed ID: 1385710)
1. Production of hybrid bispecific antibody recognizing human colorectal carcinoma and CD3 antigen.
Xiang J; Pan Z; Attah-Poku S; Babiuk L; Zhang Y; Liu E
Mol Biother; 1992 Mar; 4(1):15-23. PubMed ID: 1385710
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4.
Xiang J; Moyana T; Kalra J; Hamilton T; Qi Y
Mol Biother; 1992 Dec; 4(4):174-83. PubMed ID: 1476671
[TBL] [Abstract][Full Text] [Related]
3. Recombinant mouse/human chimeric anti-colorectal carcinoma antibody cACT19.
Xiang J; Moyana T; Liu E
Hum Antibodies Hybridomas; 1994; 5(3-4):105-15. PubMed ID: 7756575
[TBL] [Abstract][Full Text] [Related]
4. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
5. Retrovirus-derived shuttle vectors in the generation of murine bispecific MoAbs to be used in ex vivo and in vivo immunotherapy.
Demonte LB; Dellabona P; Nisticò P; Tecce R; Camagna M; Reyna A; Momo M; Natali PG; Mariani M; Malavasi F
Ann Ist Super Sanita; 1991; 27(1):133-7. PubMed ID: 1835569
[TBL] [Abstract][Full Text] [Related]
6. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
7. Induction of functional activities of human lymphocytes by monoclonal antibodies.
Melioli G; Prigione I; Merlì A; Cantoni C; Chen Q; Machi AM; Ferrini S
Ann Ist Super Sanita; 1991; 27(1):79-85. PubMed ID: 1835570
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal anti-CD44 antibody acts in synergy with anti-CD2 but inhibits anti-CD3 or T cell receptor-mediated signaling in murine T cell hybridomas.
Guo YJ; Ma J; Wong JH; Lin SC; Chang HC; Bigby M; Sy MS
Cell Immunol; 1993 Nov; 152(1):186-99. PubMed ID: 7694807
[TBL] [Abstract][Full Text] [Related]
10. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
11. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
12. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies.
Clark M; Bindon C; Dyer M; Friend P; Hale G; Cobbold S; Calne R; Waldmann H
Eur J Immunol; 1989 Feb; 19(2):381-8. PubMed ID: 2522881
[TBL] [Abstract][Full Text] [Related]
13. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
14. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific MAbs.
De Monte L; Nisticó P; Tecce R; Dellabona P; Momo M; Tarditi L; Natali PG; Mariani M; Malavasi F
Dev Biol Stand; 1990; 71():15-22. PubMed ID: 2401381
[TBL] [Abstract][Full Text] [Related]
16. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of anticolorectal carcinoma Fv molecule in myeloma cells.
Xiang J
Mol Biother; 1992 Jun; 4(2):70-6. PubMed ID: 1515097
[TBL] [Abstract][Full Text] [Related]
18. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
19. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation.
Verwilghen J; Baroja ML; Van Vaeck F; Van Damme J; Ceuppens JL
Immunology; 1991 Feb; 72(2):269-76. PubMed ID: 1826671
[TBL] [Abstract][Full Text] [Related]
20. Construction, expression, and biologic activity of murine/human chimeric antibodies with specificity for the human alpha/beta T cell receptor.
Shearman CW; Kanzy EJ; Lawrie DK; Li YW; Thammana P; Moore GP; Kurrle R
J Immunol; 1991 Feb; 146(3):928-35. PubMed ID: 1824850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
